logo
Site Network

Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Institute Cancer Westerly - Site D'angers

+33241352700
sophie.abadie-lacourtoisie@ico.unicancer.mssante.fr
Source: Site record.
http://www.institut-cancerologie-ouest.com

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

The Institut de Cancérologie de l’Ouest (ICO) is a Comprehensive Cancer Center whose missions are patient care, research, and education.From rapid diagnosis to surgery, chemotherapy, and radiotherapy, its services also include supportive care. Specializing in oncology, ICO professionals support patients throughout every stage of their care journey in a personalized, innovative, and multidisciplinary manner.

Business Status

Source: Human-provided. OPEN

Business Category

Source: Human-provided. Hospital

Business Subcategory

Source: Human-provided. Hospital
Source: Trial-derived.
79Total Trials
Source: Trial-derived.
9Recruiting Trials
Source: Trial-derived.
12Active Trials
Source: Trial-derived.
0Completed Trials
Source: Trial-derived.
124Unique Conditions
Source: Trial-derived.
104Unique Sponsors

Conditions

Source: Trial-derived. Breast Cancer (12)Source: Trial-derived. Ovarian Cancer (5)Source: Trial-derived. Advanced Solid Tumor (4)Source: Trial-derived. Colorectal Cancer (3)Source: Trial-derived. Metastatic Breast Cancer (3)Source: Trial-derived. Prostate Cancer (3)Source: Trial-derived. Cancer (2)Source: Trial-derived. Germ Cell Tumor (2)

Sponsors

Source: Trial-derived. UNICANCER (21)Source: Trial-derived. Merck Sharp & Dohme LLC (6)Source: Trial-derived. National Cancer Institute, France (6)Source: Trial-derived. Hoffmann-La Roche (5)Source: Trial-derived. Institut Cancerologie de l'Ouest (5)Source: Trial-derived. Institut Claudius Regaud (5)Source: Trial-derived. Centre Leon Berard (4)Source: Trial-derived. Pfizer (4)

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Electrocardiography (lead count not stated)
Source: AI-inferred. SPECT / nuclear medicine

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Histology / pathology
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Biobanking

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Radiation therapy

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot